Molecular structure and pharmacological mechanism of sunitinib

Sunitinib is an oral small molecule multi-target tyrosine kinase inhibitor, mainly used to treat various solid tumors such as renal cell carcinoma and gastrointestinal stromal tumor (GIST). Its unique molecular structure and multi-target mechanism make it play an important role in anti-tumor treatment, especially in inhibiting angiogenesis and tumor cell proliferation.

From a molecular structure perspective, sunitinib is an indole ring-containing compound and has a typical structure of a small molecule tyrosine kinase inhibitor. Its chemical name isN-[2-(Dimethylamino)ethyl]-5-[[(Z)-(5-Fluoro-2-Oxo< span>-1H-indole-3-subunit)methyl]amino]-2-methylbenzamide. This structure gives it good oral bioavailability, and it can penetrate the cell membrane and enter the interior of target cells, competitively binding to the ATP binding site of the tyrosine kinase receptor, thereby inhibiting the activation of the signal transduction pathway.

In terms of pharmacological mechanism, sunitinib can simultaneously inhibit multiple tyrosine kinase receptors related to tumor growth and angiogenesis, including platelet-derived growth factor receptor (PDGFR-α/β), vascular endothelial growth factor receptor (VEGFR-1 /2/3), stem cell factor receptor (c-Kit), FLT3, CSF-1R and RET, etc. By inhibiting the phosphorylation process of these receptors, sunitinib effectively blocks tumor angiogenesis, cell proliferation and metastasis, and is particularly suitable for highly vascularized tumor types.

In addition, sunitinib's multi-target properties allow it to not only directly inhibit the proliferation of tumor cells, but also indirectly "starve" cancer cells by blocking the formation of new tumor blood vessels. This dual mechanism improves the broad spectrum of its treatment and its ability to manage drug resistance. Because of this, sunitinib became one of the first targeted drugs approved for first-line treatment of advanced renal cancer and GIST, and has been proven to prolong progression-free survival and overall survival in multiple clinical studies. With the deepening of research, its combination therapy and application prospects in other solid tumors are gradually expanding.

Reference materials:https://www.sutent.com/